Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2005.11.973 on May 9 2005

Journal of Clinical Oncology, Vol 23, No 19 (July 1), 2005: pp. 4430-4438
© 2005 American Society of Clinical Oncology.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lim, S. T.
Right arrow Articles by Levine, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lim, S. T.
Right arrow Articles by Levine, A. M.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

AIDS-Related Burkitt's Lymphoma Versus Diffuse Large-Cell Lymphoma in the Pre–Highly Active Antiretroviral Therapy (HAART) and HAART Eras: Significant Differences in Survival With Standard Chemotherapy

Soon Thye Lim, Roksana Karim, Bharat N. Nathwani, Anil Tulpule, Byron Espina, Alexandra M. Levine

From the Norris Comprehensive Cancer Center; Department of Epidemiology and Biostatistics; Department of Pathology, University of Southern California Keck School of Medicine, Los Angeles, CA; and National Cancer Centre, Singapore

Address reprint requests to Alexandra M. Levine, MD, University of Southern California, 1441 Eastlake Avenue, Los Angeles, CA 90033; e-mail: alevine{at}usc.edu

PURPOSE: To compare outcomes of patients with HIV-Burkitt's lymphoma (HIV-BL) and HIV-diffuse large-cell lymphoma (HIV-DLCL) after treatment with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or M-BACOD (methotrexate, bleomycin, cyclophosphamide, etoposide) in pre–highly active antiretroviral therapy (HAART) versus HAART eras.

PATIENTS AND METHODS: Three hundred sixty-three patients with AIDS-related lymphoma diagnosed from 1982 to 2003 were reviewed retrospectively, including 262 in the pre-HAART (HIV-BL, 117; HIV-DLCL, 145) and 101 in the HAART era (HIV-BL, 18; HIV-DLCL, 83). Pre-HAART included those who did not receive HAART, and HAART era included those diagnosed after January 1997 who received HAART.

RESULTS: There were no significant differences between groups in terms of age, sex, history of injection drug use, prior AIDS, lactate dehydrogenase level, and disease stage at diagnosis. Compared with HIV-BL, HIV-DLCL was associated with significantly lower CD4 counts in the pre-HAART but not the HAART era. Although the overall median survival was similar for both groups in the pre-HAART era (HIV-BL, 6.4 months v HIV-DLCL, 8.3 months; P = .43), survival was significantly worse in patients with HIV-BL in the HAART era (HIV-BL, 5.7 months v HIV-DLCL, 43.2 months; P = .0003). Failure to attain complete remission and CD4 count less than 100 cells/mm3 independently predicted for poor survival in the pre-HAART era. In comparison, histology of HIV-BL and no attainment of complete remission were independent poor prognostic factors in the HAART era.

CONCLUSION: Survival of patients with HIV-DLCL has improved in the HAART era, along with CD4 count, whereas survival of similarly treated patients with HIV-BL remained poor. The current practice of using the same regimen for both groups of patients should be re-evaluated.

Presented as an oral presentation at the 46th Annual Meeting of the American Society of Hematology, San Diego, CA, December 4-7, 2004; published in abstract form.

Authors' disclosures of potential conflicts of interest are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
BloodHome page
A. Carbone, E. Cesarman, M. Spina, A. Gloghini, and T. F. Schulz
HIV-associated lymphomas and gamma-herpesviruses
Blood, February 5, 2009; 113(6): 1213 - 1224.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Bower, J. Stebbing, M. Tuthill, V. Campbell, J. Krell, P. Holmes, A. Ozzard, M. Nelson, B. Gazzard, and T. Powles
Immunologic recovery in survivors following chemotherapy for AIDS-related non-Hodgkin lymphoma
Blood, April 15, 2008; 111(8): 3986 - 3990.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Neuroradiol.Home page
C.L. Davies, R. Chinn, M. Nelson, M. Rasanesan, B. Gazzard, T. Powles, M. Bower, and J. Stebbing
Outcome in AIDS-Related Systemic Non-Hodgkin Lymphoma and Leptomeningeal Disease Is Not Predicted by a CT Brain Scan
AJNR Am. J. Neuroradiol., November 1, 2007; 28(10): 1988 - 1990.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
L. Galicier, C. Fieschi, R. Borie, V. Meignin, M.-T. Daniel, L. Gerard, and E. Oksenhendler
Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study
Blood, October 15, 2007; 110(8): 2846 - 2854.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
Y.-B. Chen, A. Rahemtullah, and E. Hochberg
Primary Effusion Lymphoma
Oncologist, May 1, 2007; 12(5): 569 - 576.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
T. M. Habermann
Antibody Therapy in Aggressive Lymphomas
Hematology, January 1, 2007; 2007(1): 257 - 264.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. J. Straus
Simplified prognostic indicators for AIDS-related lymphoma
Blood, May 15, 2006; 107(10): 3819 - 3820.
[Full Text] [PDF]


Home page
BloodHome page
N. Mounier, M. Spina, J. Gabarre, M. Raphael, G. Rizzardini, J.-B. Golfier, E. Vaccher, A. Carbone, B. Coiffier, G. Chichino, et al.
AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy
Blood, May 15, 2006; 107(10): 3832 - 3840.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. Stebbing, S. Mandalia, C. Palmieri, M. Nelson, B. Gazzard, and M. Bower
Burkitt's Lymphoma and Previous AIDS-Defining Illnesses Are Not Prognostic Factors in AIDS-Related Non-Hodgkin's Lymphoma
J. Clin. Oncol., November 20, 2005; 23(33): 8538 - 8540.
[Full Text] [PDF]


Home page
JCOHome page
A. M. Levine and S.-T. Lim
In Reply:
J. Clin. Oncol., November 20, 2005; 23(33): 8540 - 8541.
[Full Text] [PDF]


Home page
JCOHome page
S.-T. Lim, R. Karim, A. Tulpule, B. N. Nathwani, and A. M. Levine
Prognostic Factors in HIV-Related Diffuse Large-Cell Lymphoma: Before Versus After Highly Active Antiretroviral Therapy
J. Clin. Oncol., November 20, 2005; 23(33): 8477 - 8482.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. Spina, C. Simonelli, R. Talamini, and U. Tirelli
Patients With HIV With Burkitt's Lymphoma Have a Worse Outcome Than Those With Diffuse Large-Cell Lymphoma Also in the Highly Active Antiretroviral Therapy Era
J. Clin. Oncol., November 1, 2005; 23(31): 8132 - 8133.
[Full Text] [PDF]


Home page
JCOHome page
S.-T. Lim, R. Karim, B. N. Nathwani, A. Tulpule, and A. M. Levine
In Reply:
J. Clin. Oncol., November 1, 2005; 23(31): 8133 - 8134.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2005 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online